Cart
sales@molnova.com
CDK1-IN-2
CAS No. 220749-41-7
CDK1-IN-2( —— )
Catalog No. M35812 CAS No. 220749-41-7
CDK1-IN-2 (cdk1 inhibitor 2) is a CDK1 inhibitor with IC50 of 5.8 μM. A broad-spectrum kinase profiling of CDK1-IN-2 revealed nonselective inhibition of several kinases.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 100 | In Stock |
|
| 5MG | 104 | In Stock |
|
| 10MG | 169 | In Stock |
|
| 25MG | 353 | In Stock |
|
| 50MG | 555 | In Stock |
|
| 100MG | 792 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 1609 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCDK1-IN-2
-
NoteResearch use only, not for human use.
-
Brief DescriptionCDK1-IN-2 (cdk1 inhibitor 2) is a CDK1 inhibitor with IC50 of 5.8 μM. A broad-spectrum kinase profiling of CDK1-IN-2 revealed nonselective inhibition of several kinases.
-
DescriptionCDK1-IN-2 is a CDK1 inhibitor (IC50: 5.8 μM).
-
In VitroCDK1-IN-2 (“CDK1 inhibitor 1”, 0-19.8 μM, 24 h) arrests HCT-116 cells in G2/M phase.
-
In Vivo——
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetCDK
-
RecptorCDK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number220749-41-7
-
Formula Weight294.73
-
Molecular FormulaC17H11ClN2O
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : ≥ 250 mg/mL (848.21 mM )
-
SMILESClc1[nH]c2ccccc2c1\C=C1\C(=O)Nc2ccccc12
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Jorda R, et al. How Selective Are Pharmacological Inhibitors of Cell-Cycle-Regulating Cyclin-Dependent Kinases? J Med Chem. 2018 Oct 25;61(20):9105-9120. ?
molnova catalog
related products
-
BLU-222
BLU-222 is an orally available but selective cell cycle protein-dependent kinase (CDK2) inhibitor with antitumor activity for the study of ovarian and uterine cancer.
-
(R)-Enitociclib
(R)-Enitociclib, an enantiomer of BAY-1251152, is a CDK9 inhibitor with anticancer activity.
-
XPW1
XPW1 is a new potent and selective CDK9 inhibitor with antitumour activity that transcriptionally inhibits the DNA repair process in ccRCC cells.XPW1 can be used to study clear cell renal cell carcinoma.
